四妙丸、六君子丸干预高尿酸血症合并胰岛素抵抗大鼠模型的实验研究
Effect of Simiao Pill and Liujunzi Pill on rat model of hyperuricemia complicated with insulin resistance
- 上海中医药杂志 2021年55卷第3期 页码：81-86
- 作者机构：
1.上海中医药大学附属曙光医院风湿免疫科（上海 200021）
2.上海中医药大学附属曙光医院内分泌科（上海 200021）
3.上海中医药大学附属曙光医院肾病科（上海 200021）
- 作者简介：
杨淑芬，女，硕士研究生，主要从事中医药治疗风湿免疫疾病的临床和基础研究工作
潘新，副主任医师，硕士研究生导师；E-mail：panxin66@163.com
- 基金信息：
DOI：10.16305/j.1007-1334.2021.2011139
中图分类号：
扫 描 看 全 文
杨淑芬, 徐隽斐, 陈文浩, 等. 四妙丸、六君子丸干预高尿酸血症合并胰岛素抵抗大鼠模型的实验研究[J]. 上海中医药杂志, 2021,55(3):81-86.
Shufen YANG, Junfei XU, Wenhao CHEN, et al. Effect of Simiao Pill and Liujunzi Pill on rat model of hyperuricemia complicated with insulin resistance[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(3):81-86.
杨淑芬, 徐隽斐, 陈文浩, 等. 四妙丸、六君子丸干预高尿酸血症合并胰岛素抵抗大鼠模型的实验研究[J]. 上海中医药杂志, 2021,55(3):81-86. DOI： 10.16305/j.1007-1334.2021.2011139.
Shufen YANG, Junfei XU, Wenhao CHEN, et al. Effect of Simiao Pill and Liujunzi Pill on rat model of hyperuricemia complicated with insulin resistance[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(3):81-86. DOI： 10.16305/j.1007-1334.2021.2011139.
摘要
目的,2,研究四妙丸、六君子丸对高脂饲料联合果糖水喂养、氧嗪酸钾灌胃所致的高尿酸血症（HUA）合并胰岛素抵抗（IR）大鼠的影响。,方法,2,Wistar雄性大鼠36只，空白组6只（不予干预），其余大鼠建立HUA合并IR模型，造模成功后随机分为模型组、苯溴马隆组（苯溴马隆0.83 g/kg）、非布司他组（非布司他1.24 g/kg）、四妙丸组（四妙丸1.38 g/kg）、六君子丸组（六君子丸1.73 g/kg），每组6只。给药4周后称量各组大鼠体质量及腹腔脂肪的质量，并检测各组血尿酸（UA）、胰岛素（INS）、IR指数（HOMA-IR）、血糖（FPG）、血脂四项[总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白（LDL-c）、高密度脂蛋白（HDL-c）]、尿素氮（BUN）、肌酐（SCr）、肝脏黄嘌呤氧化酶（XOD）活性、肾脏尿酸盐重吸收转运子（URAT1）表达。,结果,2,①与空白组比较，模型组和各给药组的体质量、腹腔脂肪质量均明显增加（,P,<,0.01），四妙丸组、六君子丸组大鼠腹腔脂肪质量较模型组、苯溴马隆组、非布司他组明显减少（,P,<,0.01）。②与空白组比较，模型组UA、INS、FPG、HOMA-IR水平均显著升高（,P,<,0.05，,P,<,0.01）；与模型组比较，各给药组UA、INS、HOMA-IR水平均降低（,P,<,0.05，,P,<,0.01），其中非布司他组UA降低最为显著，四妙丸组与苯溴马隆组HOMA-IR减少最明显（,P,<,0.01）。③各组大鼠血脂、BUN、SCr水平差异均无统计学意义（,P,>,0.05）。④与模型组比较，四妙丸组、非布司他组抑制XOD活性（,P,<,0.05）。⑤与模型组比较，四妙丸、六君子丸、苯溴马隆能下调URAT1的表达（,P,<,0.01）。,结论,2,四妙丸、六君子丸具有降尿酸、改善IR的作用，为健脾清热利湿法治疗HUA合并IR提供思路。
Abstract
Objective,2,To investigate the therapeutic effects of Simiao Pill and Liujunzi Pill on hyperuricemic (HUA) rats with insulin resistance (IR) induced by high fat diet combined with fructose water feeding and potassium oxazinate intragastric administration.,Methods,2,Of the 36 male Wistar rats, 6 were in the blank group (without intervention) and the others were established the model of HUA combined with IR. After successful modeling, they were randomly divided into 5 groups: model group, benzbromarone group (benzbromarone 0.83 g/kg), febutastat group (febutastat 1.24 g/kg), Simiao Pill group (Simiao Pill 1.38 g/kg), Liujunzi Pill group (Liujunzi Pill 1.73 g/kg), with 6 rats in each group. After 4 weeks of drug administration, the body weight and the abdomin-fat weight of the rats were recorded, and indexes including serum uric acid (UA), insulin (INS), insulin resistance index(HOMA-IR), fasting serum glucose (FPG) fasting serum lipid [total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-c), high density lipoprotein (HDL-c)], urea nitrogen (BUN), creatinine (SCr), liver xanthine oxidase (XOD) activity and renal uric acid transporter URAT1 expression were detected.,Results,2,①The body weight and abdomin-fat weight of the model group and the administration groups were significantly higher than those of the blank group (,P,<,0.01), while the abdominal-fat of Simiao Pill group and Liujunzi Pill group was significantly lower than that of the model group, benzbromarone group and febutastat group. ②UA, INS, FPG and HOMA-IR in the model group were significantly higher than those in the blank group (,P,<,0.05,P,<,0.01). The levels of UA, INS and HOMA-IR in the administration groups were lower than those in the model group (,P,<,0.05,P,<,0.01). Among them, the decrease of UA was most significant in the febuxostat group (,P,<,0.01) and the reduction of HOMA-IR was most significant in the Simiao Pill and the benzbromarone group (,P,<,0.01).③There were no significant difference in serum lipids, BUN, and SCr among all groups (,P,>,0.05). ④Compared with the model group, Simiao Pill and febuxostat inhibited the activity of XOD (,P,<,0.05).⑤ Compared with the model group, Simiao Pill, Liujunzi Pill and benzbromarone down-regulated the expression of URAT1 (,P,<,0.01).,Conclusion,2,Simiao Pill and Liujunzi Pill can reduce UA and improve IR, which provide an idea for the treatment of HUA complicated with IR by fortifying the spleen, clearing heat and disinhibiting dampness.
关键词
高尿酸血症胰岛素抵抗大鼠四妙丸六君子丸
Keywords
hyperuricemiainsulin resistanceratsSimiao PillLiujunzi Pill
references
MATTIUZZI C, LIPPI G. Recent updates on worldwide gout epidemiology[J]. Clin Rheumatol, 2020, 39(4): 1061-1063.
费菲. 古洁若. 高尿酸血症及痛风的过去、现在和未来[J]. 中国医药科学,2019, 9(10): 4-6.
曾小峰，陈耀龙. 2016中国痛风诊疗指南[J]. 浙江医学,2017, 39(21): 1823-1832.
LI R, YU K, LI C. Dietary factors and risk of gout and hyperuricemia: a meta-analysis and systematic review[J]. Asia Pac J Clin Nutr, 2018, 27(6): 1344-1356
RAI S K, FUNG T T, LU N, et al. The Dietary Approaches to Stop Hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study[J]. BMJ, 2017(357): j1794.
STANHOPE K L. Sugar consumption, metabolic disease and obesity: the state of the controversy[J]. Crit Rev Clin Lab Sci, 2016, 53(1): 52-67.
LEE Y S, KIM S H, YUK H J, et al. Tetragonia tetragonoides (Pall.) Kuntze (New Zealand Spinach) prevents obesity and hyperuricemia in high-fat diet-induced obese mice[J]. Nutrients, 2018, 10(8): 1087.
ECKEL R H, GRUNDY S M, ZIMMET P Z. The metabolic syndrome[J]. Lancet, 2005, 365(9468): 1415-1428.
MEDINA G, VERA-LASTRA O, PERALTA-AMARO A L, et al. Metabolic syndrome, autoimmunity and rheumatic diseases[J]. Pharmacol Res, 2018(133): 277-288.
THOTTAM G E, KRASNOKUTSKY S, PILLINGER M H. Gout and metabolic syndrome: a tangled web[J]. Curr Rheumatol Rep, 2017, 19(10): 60.
刘李玟韬，杨洁，陈秉朴. 高尿酸血症动物模型研究述评[J]. 湖南中医药大学学报,2017, 37(12): 1431-1436.
ANTUNES L C, ELKFURY J L, JORNADA M N, et al. Validation of HOMA-IR in a model of insulin-resistance induced by a high-fat diet in Wistar rats[J]. Arch Endocrinol Metab, 2016, 60(2): 138-142.
USEMANN J, FREY U, MACK I, et al. CHI3L1 polymorphisms, cord blood YKL-40 levels and later asthma development[J]. BMC Pulm Med, 2016, 16(1): 81.
魏伟. 药理实验方法学（第四版）[M].北京：人民卫生出版社，2010.
BARDIN T, RICHETTE P. Impact of comorbidities on gout and hyperuricaemia： an update on prevalence and treatment options[J]. BMC Med, 2017, 15(1): 123.
GENONI G, MENEGON V, SECCO G G, et al. Insulin resistance, serum uric acid and metabolic syndrome are linked to cardiovascular dysfunction in pediatric obesity[J]. Int J Cardiol, 2017 (249): 366-371.
ADNAN E, RAHMAN I A, FARIDIN H P. Relationship between insulin resistance, metabolic syndrome components and serum uric acid[J]. Diabetes Metab Syndr, 2019, 13(3): 2158-2162.
WAN X, XU C, LIN Y, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism[J]. J Hepatol, 2016, 64(4): 925-932.
KING C, LANASPA M A, JENSEN T, et al. Uric acid as a cause of the metabolic syndrome[J]. Contrib Nephrol, 2018(192): 88-102.
朱丽梅，李显丽. 高尿酸血症导致糖代谢异常相关机制的研究进展[J]. 医学综述,2019, 25(22): 4509-4514.
胡天祥. 基于尿酸与血脂代谢关系探讨加减四妙丸的作用机制[D]. 广州：广州中医药大学，2018.
邓耒娇，闫洁熙，王沛，等. 茯苓多糖对高尿酸血症大鼠肾小管转运体rURAT1、rOAT1和rOCT2表达的影响[J]. 西部中医药,2019, 32(6): 10-14.
张双金，周燕，魏玉辉，等. 茯苓水提物对高尿酸血症大鼠rURAT1 rOAT1和rOCT2表达的影响[J]. 西部医学,2016, 28(12): 1648-1651.
王泽，慈小燕，崔涛，等. 不同药性成分对OAT4、URAT1抑制作用及对急性高尿酸血症小鼠血尿酸水平的影响[J]. 中草药,2019, 50(5): 1157-1163.
郭敏. 甘草多糖降尿酸作用及颗粒剂的研究[D].镇江：江苏大学，2018.
张瑞城，钟良宝，梁海琴，等. 异甘草素对黄嘌呤氧化酶抑制的影响及机制[J]. 中国老年学杂志,2015, 35(17): 4757-4759.
郭丙花. 草木樨属与柑橘属药材抑制黄嘌呤氧化酶物质基础研究[D]. 青岛：青岛大学，2016.
ZHU Y, PENG X, LING G. An update on the animal models in hyperuricaemia research[J]. Clin Exp Rheumatol, 2017, 35(5): 860-864.
吴燕升，万强，史丽强，等. 高尿酸血症肾纤维化动物模型研究进展[J]. 成都医学院学报,2016, 11(6): 747-750.
0
浏览量
330
下载量
0
CSCD
3
CNKI被引量
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 沪ICP备13044091号
沪公网安备 31011502015228号 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
- 总访问量：70551 今日访问量：32